VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.1658
-0.0066 (-3.83%)
Apr 10, 2026, 4:00 PM EDT - Market closed
VolitionRx Revenue
In the year 2025, VolitionRx had annual revenue of $1.73M with 40.04% growth. VolitionRx had revenue of $447.03K in the quarter ending December 31, 2025, with 133.25% growth.
Revenue (ttm)
$1.73M
Revenue Growth
+40.04%
P/S Ratio
15.21
Revenue / Employee
$23,032
Employees
75
Market Cap
26.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.73M | 493.87K | 40.04% |
| Dec 31, 2024 | 1.23M | 458.21K | 59.10% |
| Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
| Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
| Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Nortech Systems | 118.37M |
| TELA Bio | 80.28M |
| Myomo | 40.93M |
| Cytosorbents | 37.06M |
| Lifeward | 22.03M |
| Pulsenmore | 12.55M |
| NeuroOne Medical Technologies | 11.72M |
| IceCure Medical | 3.38M |
VNRX News
- 10 days ago - VolitionRx Limited Announces Full Fiscal Year 2025 Financial Results and Business Update - PRNewsWire
- 11 days ago - VolitionRx Secures EUR 2.0 Million of Non-Dilutive Funding from Regional Government Agencies in Belgium - PRNewsWire
- 12 days ago - Volition Announces Mayo Clinic Study Demonstrates Nu.Q® Concentrations are Elevated in Trauma Patients - PRNewsWire
- 16 days ago - Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer Conference - PRNewsWire
- 16 days ago - VolitionRx Limited Schedules Full Fiscal Year 2025 Earnings Conference Call and Business Update - PRNewsWire
- 17 days ago - Volition Announces Detection of Over 95% of Early-Stage Cancers - PRNewsWire
- 24 days ago - Volition Reports Breakthrough in Liquid Biopsy: Achievement of over 99% Purity in Isolating Cancer DNA - PRNewsWire
- 5 weeks ago - Volition Announces First Ever Automated Nu.Q® Vet Cancer Test with Fujifilm Vet Systems - PRNewsWire